title: Acute renal failure associated with the new BRAF inhibitor vemurafenib: a case series of 8 patients.
abstract: BACKGROUND
  Vemurafenib is a BRAF inhibitor that has become the cornerstone of metastatic or inoperable melanoma therapy since its approval in 2011 in the United States and 2012 in Europe. This targeted therapy has shown impressive results in terms of increased progression-free and overall survival as compared to dacarbazine. The safety profile did not include any renal manifestations at that time.
  
  
  METHODS
  This report is the first case series of 8 patients who experienced significant to severe renal insufficiency under vemurafenib treatment.
  
  
  RESULTS
  This case series shows that vemurafenib may induce potentially severe acute renal failure, including renal sequelae and persistent kidney disease in some cases.
  
  
  CONCLUSIONS
  Further studies are needed to investigate the effects of vemurafenib on the kidneys. Meanwhile, renal function should be closely monitored in treated patients for early detection of any renal dysfunction occurrence. Cancer 2014;120:2158-2163. © 2014 American Cancer Society.
authors.affiliation: Service ICAR, Centre Hospitalier Universitaire (CHU) Pitié-Salpêtrière, Paris, France; Nephrology Department, CHU Pitié-Salpêtrière, Paris, France.
authors.forename: Vincent
authors.initials: V
authors.lastname: Launay-Vacher
authors.forename: Sarah
authors.initials: S
authors.lastname: Zimner-Rapuch
authors.forename: Nicolas
authors.initials: N
authors.lastname: Poulalhon
authors.forename: Thibault
authors.initials: T
authors.lastname: Fraisse
authors.forename: Valérie
authors.initials: V
authors.lastname: Garrigue
authors.forename: Morgane
authors.initials: M
authors.lastname: Gosselin
authors.forename: Sabine
authors.initials: S
authors.lastname: Amet
authors.forename: Nicolas
authors.initials: N
authors.lastname: Janus
authors.forename: Gilbert
authors.initials: G
authors.lastname: Deray
mesh_terms: D058186:Acute Kidney Injury / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007211:Indoles / Q000008:administration & dosage / Q000009:adverse effects*; D007668:Kidney / Q000187:drug effects* / Q000503:physiopathology; D007677:Kidney Function Tests; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D008875:Middle Aged; D048493:Proto-Oncogene Proteins B-raf / Q000037:antagonists & inhibitors*; D012720:Severity of Illness Index; D012878:Skin Neoplasms / Q000188:drug therapy; D013449:Sulfonamides / Q000008:administration & dosage / Q000009:adverse effects*; D017211:Treatment Failure; D016896:Treatment Outcome; D000077484:Vemurafenib
chemical_list: D000970:Antineoplastic Agents; D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf
keywords: acute renal failure; nephrotoxicity; renal insufficiency; side effect; vemurafenib